Centene
Market Cap
US$38.4b
Last Updated
2020/02/23 01:06 UTC
Data Sources
Company Financials +
Executive Summary
Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record and good value.
Similar Companies
Share Price & News
How has Centene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CNC has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.8%
CNC
0.2%
US Healthcare
-1.1%
US Market
1 Year Return
2.3%
CNC
12.4%
US Healthcare
17.9%
US Market
Return vs Industry: CNC underperformed the US Healthcare industry which returned 12.4% over the past year.
Return vs Market: CNC underperformed the US Market which returned 17.9% over the past year.
Shareholder returns
| CNC | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.8% | 0.2% | -1.1% |
| 30 Day | -1.7% | 2.8% | 1.4% |
| 90 Day | 7.1% | 5.6% | 6.9% |
| 1 Year | 2.3%2.3% | 13.9%12.4% | 20.3%17.9% |
| 3 Year | 85.5%85.5% | 49.6%43.0% | 47.8%38.3% |
| 5 Year | 113.1%113.1% | 61.4%50.3% | 71.9%53.0% |
Price Volatility Vs. Market
How volatile is Centene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
If You Like EPS Growth Then Check Out Centene (NYSE:CNC) Before It's Too Late1 week ago | Simply Wall St
Do Institutions Own Centene Corporation (NYSE:CNC) Shares?3 weeks ago | Simply Wall St
Did You Miss Centene's (NYSE:CNC) Impressive 119% Share Price Gain?Valuation
Is Centene undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CNC ($65.49) is trading below our estimate of fair value ($144.65)
Significantly Below Fair Value: CNC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CNC is good value based on its PE Ratio (20.5x) compared to the Healthcare industry average (29.8x).
PE vs Market: CNC is poor value based on its PE Ratio (20.5x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: CNC is poor value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: CNC is good value based on its PB Ratio (2.2x) compared to the US Healthcare industry average (3x).
Next Steps
Future Growth
How is Centene forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
20.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNC's forecast earnings growth (20.4% per year) is above the savings rate (1.7%).
Earnings vs Market: CNC's earnings (20.4% per year) are forecast to grow faster than the US market (14.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CNC's revenue (12.4% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: CNC's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CNC's Return on Equity is forecast to be low in 3 years time (12.1%).
Next Steps
Past Performance
How has Centene performed over the past 5 years?
31.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CNC has high quality earnings.
Growing Profit Margin: CNC's current net profit margins (1.9%) are higher than last year (1.6%).
Past Earnings Growth Analysis
Earnings Trend: CNC's earnings have grown significantly by 31.5% per year over the past 5 years.
Accelerating Growth: CNC's earnings growth over the past year (46.8%) exceeds its 5-year average (31.5% per year).
Earnings vs Industry: CNC earnings growth over the past year (46.8%) exceeded the Healthcare industry 13.9%.
Return on Equity
High ROE: CNC's Return on Equity (10.3%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Centene's financial position?
Financial Position Analysis
Short Term Liabilities: CNC's short term assets ($20.3B) exceed its short term liabilities ($12.9B).
Long Term Liabilities: CNC's short term assets ($20.3B) exceed its long term liabilities ($15.4B).
Debt to Equity History and Analysis
Debt Level: CNC's debt to equity ratio (107.3%) is considered high.
Reducing Debt: CNC's debt to equity ratio has increased from 46.6% to 107.3% over the past 5 years.
Debt Coverage: CNC's debt is not well covered by operating cash flow (10.9%).
Interest Coverage: CNC's interest payments on its debt are well covered by EBIT (6.2x coverage).
Balance Sheet
Inventory Level: CNC has a low level of unsold assets or inventory.
Debt Coverage by Assets: CNC's debt is covered by short term assets (assets are 1.5x debt).
Next Steps
Dividend
What is Centene's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CNC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CNC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CNC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CNC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CNC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.9yrs
Average management tenure
CEO
Michael Neidorff (76yo)
23.8yrs
Tenure
US$26,122,414
Compensation
Mr. Michael Frederic Neidorff has been Chairman and Chief Executive Officer of Centene Corporation since May 2004 and its President since April 23, 2019. From May 1996 to May 2004, Mr. Neidorff served as P ...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD26.12M) is above average for companies of similar size in the US market ($USD10.81M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 23.8yrs | US$26.12m | 1.11% $428.3m | |
| Executive VP | 3.9yrs | US$9.96m | 0.031% $12.0m | |
| Executive VP & COO | 0yrs | US$7.57m | 0.024% $9.1m | |
| Executive VP & Chief Information Officer | 3.8yrs | US$4.04m | 0.0095% $3.6m | |
| Executive VP & Chief Strategy Officer | 7.2yrs | US$6.16m | 0.060% $23.0m | |
| Senior VP | 3.8yrs | no data | 0.0032% $1.2m | |
| Senior Vice President of Finance & Investor Relations | 12.8yrs | no data | no data | |
| Senior Vice President | 0yrs | no data | 0.017% $6.6m | |
| Senior Vice President of Internal Audit | 1.2yrs | no data | no data | |
| Senior Vice President of Human Resources | 0yrs | no data | no data |
3.9yrs
Average Tenure
50.5yo
Average Age
Experienced Management: CNC's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 23.8yrs | US$26.12m | 1.11% $428.3m | |
| Independent Director | 16.8yrs | US$387.06k | 0.0010% $392.0k | |
| Independent Director | 13.8yrs | US$359.56k | 0.026% $10.2m | |
| Independent Director | 15.9yrs | US$402.06k | 0.033% $12.9m | |
| Presiding Director | 0yrs | US$402.06k | 0.15% $56.1m | |
| Independent Director | 8.4yrs | US$337.06k | 0.031% $11.8m | |
| Chairman of University Health Plans | 15.3yrs | no data | no data | |
| Independent Director | 14.8yrs | US$387.06k | 0.032% $12.3m | |
| Independent Director | 13.2yrs | US$362.06k | 0.011% $4.3m | |
| Director | 2yrs | US$697.95k | 0.0017% $653.3k |
14.8yrs
Average Tenure
71.5yo
Average Age
Experienced Board: CNC's board of directors are seasoned and experienced ( 14.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CNC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6%.
Top Shareholders
Company Information
Centene Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Centene Corporation
- Ticker: CNC
- Exchange: NYSE
- Founded: 1984
- Industry: Managed Health Care
- Sector: Healthcare
- Market Cap: US$38.427b
- Shares outstanding: 586.77m
- Website: https://www.centene.com
Number of Employees
Location
- Centene Corporation
- Centene Plaza
- 7700 Forsyth Boulevard
- St. Louis
- Missouri
- 63105
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CNC | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Dec 2001 |
| QEN | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Dec 2001 |
| 0HVB | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Dec 2001 |
| CNC * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Dec 2001 |
| QEN | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Dec 2001 |
| C1NC34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH REPR 1 COM | BR | BRL | Dec 2019 |
Biography
Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. The company’s Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children’s health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which covers dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions, limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. Its Specialty Services segment provides pharmacy benefits management services; health, triage, wellness, and disease management services; and vision and dental, and management services, as well as care management software that automate the clinical, administrative, and technical components of care management programs. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/23 01:06 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.